School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong, China.
Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China,
Clin Interv Aging. 2019 Feb 20;14:399-406. doi: 10.2147/CIA.S192435. eCollection 2019.
We performed a meta-analysis to evaluate the efficacy and safety of dutasteride and finasteride in treating men with androgenetic alopecia (AGA) during a 24-week treatment cycle.
Randomized controlled trials of dutasteride and finasteride for treating AGA were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were calculated using Rev Man v5.3.0. The reference lists of retrieved studies were also investigated.
Three articles including 576 participants which compared dutasteride with finasteride were selected for our analysis. The mean change in total hair count (mean difference [MD], 28.57; 95% CI, 18.75-38.39; <0.00001), investigator's assessment of global photographs for the vertex (MD, 0.68; 95% CI, 0.13-1.23; =0.02) and frontal (MD, 0.63; 95% CI, 0.13-1.13; =0.01) views, panel global photographic assessment for the vertex (MD, 0.17; 95% CI, 0.09-0.24; <0.00001) and frontal (MD, 0.25; 95% CI, 0.18-0.31; <0.00001) views, and subjects' assessment (MD, 0.56; 95% CI, 0.18-0.94; =0.003) suggested that dutasteride provided a better efficacy in treating men with AGA compared with finasteride. With regard to the assessment of safety, altered libido (=0.54), erectile dysfunction (=0.07), and ejaculation disorders (=0.58), dutasteride did not show a significant difference compared with finasteride.
Dutasteride seems to provide a better efficacy compared with finasteride in treating AGA. The two drugs appear to show similar rates of adverse reactions, especially in sexual dysfunction.
我们进行了一项荟萃分析，以评估在 24 周治疗周期中，度他雄胺和非那雄胺治疗雄激素性脱发（AGA）男性的疗效和安全性。
使用 MEDLINE、EMBASE 和 Cochrane 对照试验注册库搜索度他雄胺和非那雄胺治疗 AGA 的随机对照试验。使用 Rev Man v5.3.0 计算数据。还研究了检索研究的参考文献列表。
选择了三项比较度他雄胺和非那雄胺的研究，共 576 名参与者纳入我们的分析。总发量的平均变化（均数差 [MD]，28.57；95%CI，18.75-38.39；<0.00001）、研究者对顶点的整体照片评估（MD，0.68；95%CI，0.13-1.23；=0.02）和前额（MD，0.63；95%CI，0.13-1.13；=0.01）视图、顶点的小组整体照片评估（MD，0.17；95%CI，0.09-0.24；<0.00001）和前额（MD，0.25；95%CI，0.18-0.31；<0.00001）视图以及受试者评估（MD，0.56；95%CI，0.18-0.94；=0.003）表明，与非那雄胺相比，度他雄胺在治疗 AGA 男性方面的疗效更好。关于安全性评估，性欲改变（=0.54）、勃起功能障碍（=0.07）和射精障碍（=0.58），度他雄胺与非那雄胺相比没有显著差异。
与非那雄胺相比，度他雄胺在治疗 AGA 方面似乎疗效更好。两种药物的不良反应发生率似乎相似，尤其是在性功能障碍方面。
